Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2– breast cancer in the US
Compared to no testing, the full testing strategy of genetic and genomic testing was more effective at a lower cost or was cost-effective, supporting the goal to increase the survival and the quality-of-life of women with breast cancer along the cancer care continuum.
Authors
- Quang A. Le (ORCID: https://orcid.org/0000-0002-4968-9334)
- Jennifer M. Racz (ORCID: https://orcid.org/0000-0003-4176-5598)
- Bradley A. Arrick (ORCID: https://orcid.org/0000-0002-7926-6658)
- Deborah Hartzfeld (ORCID: https://orcid.org/0000-0002-0127-8114)
- Steve Millen
- Brandie Heald
- M. Gouldson
- V. Berdunov
- J.-P. De La O
- S. Eymere
- G. Cuyun Carter
Institutions
- Exact Sciences (United States) (US)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1080/13696998.2026.2626242
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00